Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis

Cancer
Mary-Elizabeth M PercivalChristina A Clarke

Abstract

Acute myeloid leukemia (AML) is treated with conventional induction chemotherapy shortly after diagnosis for the majority of patients aged ≤ 65 years. A recent report suggested a substantial decline in the early, or 1-month, mortality rate in patients treated on clinical trials over the past 2 decades. It is unknown whether a similar improvement has been observed in the general population. The authors examined the 1-month mortality rate in a large population-based series of 9380 patients with AML who were aged ≤ 65 years and were diagnosed and treated with chemotherapy between 1973 and 2010. A significant decline was observed in the 1-month mortality rate from 18.7% among patients diagnosed from 1973 through 1977 (95% confidence interval [95% CI], 16.4%-21.2%) to 5.8% for those diagnosed between 2008 and 2010 (95% CI, 4.5%-7.6%) (P <.001). The median overall survival improved significantly from 6 months (95% CI, 5 months-7 months) in 1973 to 1977 to 23 months (95% CI, 16 months-20 months) in 2008 to 2010 (P <.001). Although age and geographic variation were found to significantly influence the 1-month mortality for the period between 1973 and 1977, these differences in 1-month mortality were no longer significant among patients...Continue Reading

References

Jul 19, 2002·Archives of Internal Medicine·Joseph MenzinRajiv Mallick
Dec 6, 2005·Drugs & Aging·Kathleen LangJoseph Menzin
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Jan 26, 2007·The New England Journal of Medicine·Oliver A CornelyDavid Angulo-Gonzalez
Mar 18, 2009·British Journal of Haematology·Alan K BurnettUNKNOWN United Kingdom National Cancer Research Institute Haematological Oncology Study Group
May 2, 2009·Blood·Jacob M Rowe
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Apr 7, 2010·Proceedings of the National Academy of Sciences of the United States of America·William BlumGuido Marcucci
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Feb 15, 2011·British Journal of Haematology·Daniel A PollyeaBruno C Medeiros
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B WalterElihu H Estey
Oct 14, 2011·Haematologica·James Scott McClellanBruno C Medeiros
Jan 21, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jean Baptiste MicolHervé Dombret

❮ Previous
Next ❯

Citations

Jan 13, 2016·Leukemia & Lymphoma·Colin D GodwinRoland B Walter
Sep 15, 2015·Expert Opinion on Pharmacotherapy·Ryan C Lynch, Bruno C Medeiros
Dec 31, 2015·Current Opinion in Hematology·Yishai Ofran
Oct 12, 2017·Expert Opinion on Pharmacotherapy·Tracy Murphy, Karen W L Yee
Apr 27, 2018·Expert Opinion on Pharmacotherapy·Laura C MichaelisRoland B Walter
Dec 27, 2018·Current Opinion in Hematology·Anna B HalpernElihu H Estey
Jan 24, 2019·Expert Review of Clinical Pharmacology·Juan Eduardo Megías-VericatPau Montesinos
Dec 7, 2018·Hematology·Laura C Michaelis
Apr 18, 2019·JCO Clinical Cancer Informatics·Meghan C Ferrall-FairbanksPhilipp M Altrock
Apr 19, 2017·British Journal of Haematology·Gwendolyn HoTheresa H M Keegan
Jul 11, 2018·Cancers·Kah Poh Loh, Heidi D Klepin
Nov 25, 2018·Annals of Hematology·Ayman QasrawiRakesh Gaur
Oct 9, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Raffaele PalmieriRoland B Walter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.